Status:
WITHDRAWN
Diet, Physical Activity and Body Composition Changes During R-CHOP
Lead Sponsor:
George Washington University
Conditions:
Non-Hodgkin Lymphoma
DLBCL
Eligibility:
All Genders
18+ years
Brief Summary
In this pilot study, observational data will be collected to describe the usual trajectory of changes in dietary intake, ability to be physically active, body composition, environmental exposures, and...
Detailed Description
Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) is the "gold standard" first-line treatment for patients with non-Hodgkin lymphoma, yet it is estimated that R-CHOP i...
Eligibility Criteria
Inclusion
- Diagnosis of one of the non-Hodgkin lymphomas
- Scheduled to receive R-CHOP at the George Washington University Cancer Center
Exclusion
- Diagnosis of cancer other than one of the non-Hodgkin lymphomas
- Patients who are scheduled to receive their R-CHOP somewhere other than the George Washington University Cancer Center
- Patients who are not competent to provide informed consent to participate
Key Trial Info
Start Date :
January 1 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 1 2023
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT04293900
Start Date
January 1 2021
End Date
December 1 2023
Last Update
October 6 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Milken Institute School of Public Health, George Washington University
Washington D.C., District of Columbia, United States, 20052